Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter

NCT01229254 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

189

Enrollment

INDUSTRY

Sponsor class

Conditions

Atrial Fibrillation
Atrial Flutter

Interventions

DRUG: Amiodarone
DRUG: Betrixaban 60 mg
DRUG: Betrixaban 90 mg
DRUG: Betrixaban 30 mg

Sponsor

Portola Pharmaceuticals